India's drug regulator allows concurrent applications for genetic-related trials

DNA
DNA

Applications for clinical trials on genetic candidates in India can be sent at the same time to the Drug Controller General of India and the Review Committee on Genetic Manipulation under the Department of Biotechnology as part of an effort to streamline the process.

In a circular, the Drug Controller General of India, or DCGI, said the joint filing was approved at a meeting earlier this month, though it will have the final word on approval.

"It was decided in the meeting that the applicant may submit parallel application to RCGM (Review Committee on Genetic Manipulation) and DCGI seeking approval to conduct (a) clinical trial," DCGI chief G.N. Singh said in the notice.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

However (the) DCGI shall complete the scrutiny of (the) application and issue permission, only after RCGM clearance was received."

The RCGM is charged under law with reviewing the safety and ethics of recombinant DNA projects and activities in India that involve genetically engineered organisms, as well as setting guidelines, and previously had the first look at any applications.

According to the Regulatory Affairs Professionals Society, the change could shorten the path to clinical trial regulatory clearances for insulin or monoclonal antibody (mAb) candidates.

In July, the DCGI tweaked biosimilar approval guidelines and narrowed the scope to issue waivers required to run Phase III trials and rely on clinical references to biologic drugs not marketed yet in the country as part of an effort to get a better handle on data used to support such work.

- here's the notice (PDF)
- and a story from RAPS

Related Article:
India tweaks biosimilar guidelines to narrow waivers in clinical trials

Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.